{
  "ticker": "ROG",
  "year": 2019,
  "name": "ROG",
  "ir_url": "",
  "data": {
    "Income Statement": {
      "Total net sales": "61,466",
      "Research and development (R&D) costs": "11,738",
      "Selling, general and administration (SG&A) costs": "18,329",
      "Operating profit": "16,487",
      "Net income": "14,106",
      "Cost of sales": "34,979",
      "Marketing and distribution": "11,426",
      "General and administration": "4,550",
      "Other operating income": "2,177",
      "Other operating expense": "2,360"
    },
    "Balance Sheet": {
      "Cash and cash equivalents": "5,345",
      "Accounts receivable": "11,199",
      "Inventories": "9,343",
      "Total current assets": "32,948",
      "Property, plant and equipment": "17,468",
      "Goodwill": "8,734",
      "Intangible assets": "10,685",
      "Total non-current assets": "54,017",
      "Total assets": "86,965",
      "Accounts payable": "5,826",
      "Other current liabilities": "13,318",
      "Short-term debt": "1,157",
      "Total current liabilities": "20,301",
      "Long-term debt": "18,280",
      "Total non-current liabilities": "28,065",
      "Total liabilities": "48,366",
      "Equity attributable to Roche shareholders": "38,089",
      "Total equity": "38,599"
    },
    "Cash Flow Statement": {
      "Cash flows from operating activities": "19,927",
      "Cash flows from investing activities": "-7,104",
      "Cash flows from financing activities": "-11,302",
      "Net effect of currency translation on cash": "-93",
      "Increase in cash and cash equivalents": "1,428",
      "Cash and cash equivalents at beginning of year": "3,917",
      "Cash and cash equivalents at end of year": "5,345",
      "Purchase of property, plant and equipment": "-4,534"
    }
  },
  "tokens_used": 156806
}